Replimune Group (REPL) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price targets for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they predict the company's share price to reach $51.80 in the next year. This suggests a possible upside of 129.6% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.

Replimune Group's stock was trading at $27.20 at the beginning of 2023. Since then, REPL stock has decreased by 17.1% and is now trading at $22.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our REPL earnings forecast.

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05.

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust Innovation Leaders ETF (ILDR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.70%), BlackRock Inc. (6.39%), State Street Corp (5.13%), BVF Inc. IL (3.78%), FMR LLC (2.04%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, Robert Coffin and Sushil Patel.
View institutional ownership trends.

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REPL stock can currently be purchased for approximately $22.56.

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.30 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

The company employs 152 workers across the globe.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.